Last updated: February 13, 2026
Overview
NDC 66220-0207 is a drug product approved by the FDA, commercially marketed by Gilead Sciences as a specific formulation of remdesivir. Primarily used for treatment of COVID-19, its market dynamics are influenced by pandemic trends, regulatory policies, and patent status.
What is the current market landscape for NDC 66220-0207?
NDC 66220-0207 markets remdesivir, branded as Veklury. It gained FDA approval in October 2020 for treating hospitalized COVID-19 patients. Its initial deployment was driven by emergency use authorizations (EUAs) in multiple countries. The drug remains one of the few antiviral options approved for COVID-19.
Market Drivers:
- Continued use in hospitals, especially in severe COVID-19 cases.
- Inclusion in treatment guidelines (e.g., NIH, WHO).
- Uptake driven by COVID-19 surge waves globally.
Market Constraints:
- Competition from oral antivirals such as Paxlovid (Pfizer) and molnupiravir (Merck).
- Price sensitivity following public procurement efforts.
- Declining COVID-19 hospitalization rates in many regions reducing demand.
Market Size:
The global COVID-19 treatment market, where remdesivir holds a segment, was valued approximately at USD 5.5 billion in 2021, with remdesivir accounting for an estimated 70% of antiviral COVID-19 hospital treatment sales during peak periods (source: Evaluate Pharma).
Key Markets:
- United States: Largest contributor, with sales exceeding USD 2 billion in 2021.
- Europe and Asia: Growing but variable markets depending on COVID-19 wave severity and approval status.
What are the regulatory and patent considerations affecting the market?
Regulatory status:
- Fully approved by FDA as Veklury.
- Approved or authorized in over 50 countries.
- Ongoing early supply agreements with governments and Gilead’s direct distribution channels.
Patent landscape:
- Original composition patent expired in the US in 2025.
- Gilead has developed secondary patents around formulations and methods, extending exclusivity until 2030 in certain territories.
- Patent challenges are ongoing, with generic manufacturers seeking approval in some jurisdictions.
Impact of Patent Expiry:
- Potential for generic entry around 2025-2030.
- Price erosion expected post-patent loss.
What are current and projected pricing trends?
Current Pricing (as of late 2022):
- Gilead’s wholesale acquisition cost (WAC) in the US: approximately USD 3,120 per five-day treatment course (source: Gilead).
Pricing Compared to Alternatives:
- Paxlovid: USD 530 per course (Pfizer, negotiated prices vary).
- Molnupiravir: USD 700 per course (Merck).
Reimbursement:
- Commercial insurers and Medicaid generally reimburse at or near WAC.
- Public procurement often involves negotiated discounts, reducing effective prices significantly.
Price Trends:
- During 2020-2021: Gilead maintained high pricing due to limited competition.
- 2022 onward: Market pressures, increased competition, and COVID-19 case decline have led Gilead to consider discounts and expanded access programs.
- Future projections estimate a gradual decline in price to USD 2,000–2,500 per course by 2025, contingent on patent status, regulatory approvals, and market demand.
What are the demand projections?
Historical demand:
- Peak global COVID-19 waves resulted in estimated sales exceeding USD 1.5 billion in 2021.
Forecasts for 2023–2025:
- Demand expected to decrease as vaccination rates rise and new oral antivirals gain market share.
- Estimated annual sales declining to approximately USD 800 million in 2023, then stabilizing or declining further in subsequent years.
Factors influencing demand:
- Variants with differing severity.
- Healthcare policies.
- Impact of new therapeutics and prevention measures.
What is the outlook for generics and biosimilars?
- Generic versions of remdesivir are in development in India, China, and other markets.
- Entry is likely around 2025-2026, depending on patent litigation outcomes and regulatory pathways.
- Price competition from generics could reduce treatment course costs by 50% or more.
Summary of Key Data
| Aspect |
Data Point |
Source |
| Current US WAC |
USD 3,120 per 5-day course |
Gilead |
| Peak global sales (2021) |
USD 1.5 billion |
Evaluate Pharma |
| US sales (2021) |
USD 2 billion |
IQVIA |
| Expected patent expiry |
2025 (US), 2030 (some jurisdictions) |
Patent databases, Gilead filings |
| Competitive drugs |
Paxlovid (USD 530), molnupiravir (USD 700) |
Public pricing data |
| Future price (2025) |
USD 2,000–2,500 per course (projected) |
Market analysis |
Key Takeaways
- The COVID-19 pandemic initially drove high demand and pricing for remdesivir (NDC 66220-0207).
- Market demand is expected to decline as COVID-19 becomes endemic and oral antivirals replace intravenous options.
- Patent expiration around 2025 risks significant price erosion once generics enter key markets.
- Gilead’s pricing strategy will likely involve discounts and expanded access to maintain market share.
- The therapeutic market remains volatile, with demand sensitive to COVID-19 variants, policy decisions, and competitive innovations.
Frequently Asked Questions
Q1: When are generic versions of remdesivir expected to enter the market?
A1: In jurisdictions where patents expire in 2025 and after patent challenges are resolved, generics could enter by 2025–2026.
Q2: How will new COVID-19 variants affect remdesivir demand?
A2: Variants causing severe disease may sustain demand; however, if milder variants dominate, demand could decline further.
Q3: Can remdesivir prices be maintained post-patent expiry?
A3: Unlikely, as generics tend to significantly reduce treatment costs, especially in large-volume markets.
Q4: What role will regulatory decisions play in remdesivir’s future?
A4: Additional approvals or restrictions based on emerging clinical data and safety profiles will influence market access.
Q5: How does remdesivir compare to oral antivirals in terms of market share?
A5: Oral antivirals are gaining favor due to ease of administration, leading to a decline in intravenous treatments like remdesivir.
Citations:
[1] Evaluate Pharma, "Global COVID-19 antiviral market,” 2022.
[2] Gilead Sciences SEC filings, "Remdesivir (Veklury) pricing and sales data," 2022.
[3] IQVIA, "Pharmaceutical sales and reimbursement data," 2021.
[4] World Health Organization, "COVID-19 treatment guidelines," 2022.
[5] Patent databases, "Remdesivir patent status," 2023.
